培美曲塞联合顺铂二线治疗晚期肺腺癌的临床研究

目的探讨培美曲塞联合顺铂二线治疗晚期肺腺癌临床价值和用药安全性。方法通过将本院2008年1月至2012年7月32例晚期肺腺癌患者随机分成两组,观察组16例使用培美曲塞500 mg/m2,顺铂25 mg/m2,对照组16例使用多西他赛联合顺铂,静脉滴注,第1~3天,21~28d为一个周期,同时对两组进行口服地塞米松、叶酸,肌内注射维生素B12等常规治疗。2个周期后对患者病情进行一次评估。结果两组的总有效率具有统计学差异(P<0.05),观察组明显高于对照组;2组生存质量的变化具有统计学差异(P<0.05),观察组的生存质量提高稳定率高于对照组。培美曲塞联合顺铂出现的不良反应主要是胃肠反应以及骨髓抑制。结论培美曲塞联合顺铂以及常规化疗对晚期肺腺癌患者生活质量有明显改善作用,不良反应小,临床上建议进一步推广运用。

Clin/cal Research Training Pemetrexed in Combinat/on with Cisplatin Second-line Treatment of Advanced Adenocarcinoma of the Lung

Objective To investigate the clinical value of pemetrexed combined with cisplatin second-line treatment of advanced lung adenocarcinoma and medication security. Methods Our hospital in January 2008 July 2012 32 patients with advanced lung adenocarcinoma patients were randomly divided into two groups, the observer group of 16 cases of pemetrexed 500 mg/rn2, cisplatin 25 mg/m~, the control group 16 cases of the use of docetaxel in combination with cisplatin, intravenous infusion, 1-3 days, 21-28d for one cycle, while the two groups of oral dexamethasone, folic acid, intramuscular injection of vitamin B12 and other conventional treatment. Carry out an assessment on the patient＇s condition after two cycles. Results The two groups efficient statistically significant （P〈O.05）, significantly higher than that of the observation group; quality of life changes with significant difference （P 〈0.05） the quality of life of the observation group to improve the rate of stable the control group. Pemetrexed in combination with cisplatin adverse reactions are gastrointestinal reactions, as well as bone marrow suppression. Conclusion Pemetrexed in combination with cisplatin and conventional chemotherapy in patients with advanced lung adenocarcinoma patient＇s quality of life improved significantly the role of adverse reactions, clinical recommendations to further promote.